Clinical trials
T Cells clinical trials
Below are recruiting t cells clinical trials, each written for real people, not researchers. We’re tracking 5,709 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07101328RecruitingPhase 1
Study of LY4152199 for Lymphoma That Returned or Didn't Respond
This study tests a new medicine called LY4152199 for people with certain types of lymphoma (follicular or diffuse large B-cell) that came back or didn't respond to previous treatment. The goal is to see if the drug is safe and how well it works.
Duarte, CaliforniaAges 18 years+ - NCT06340737RecruitingPhase 1
CD22-targeting CAR T cells for relapsed B cell lymphoma
This trial tests whether giving modified immune cells (CAR T cells) that target CD22 on cancer cells can help people with certain B-cell lymphomas that have come back or not responded to at least two prior treatments. The goal is to see if this approach can shrink tumors or control the disease.
Palo Alto, CaliforniaAges 18 years+ - NCT06352242Recruiting
Study of immune activity after CAR-T therapy for lymphoma
This study looks at a biological process called trogocytosis (when immune cells swap pieces of their outer coating) to see if it can help predict how well CAR-T cell therapy works for people with a type of lymphoma called diffuse large B-cell lymphoma.
MontpellierAges 18 years+ - NCT06378190RecruitingPhase 1/Phase 2
New CAR-T cell therapy for relapsed B-cell lymphoma
This trial tests a new type of CAR-T cell therapy (a treatment that uses your own immune cells to fight cancer) for people with B-cell lymphomas that have come back or not responded to standard treatments. It aims to see if this new manufacturing method is safe and effective.
Barcelona, BarcelonaAges 18–80 - NCT06445803RecruitingPhase 1
CAR-T therapy for adults with certain blood cancers
This trial tests a type of immunotherapy called CAR-T cells that target two proteins (CD19 and CD22) on cancer cells. It may be an option for adults with B-cell acute lymphoblastic leukemia (ALL) or B-cell non-Hodgkin lymphoma (NHL) that has come back or not responded to earlier treatments.
Nanchang, JiangxiAges 18 years+ - NCT06550141RecruitingPhase 2
Preventing side effects of CAR-T therapy for large B-cell lymphoma
This trial tests if the drug emapalumab can help prevent toxic side effects often caused by CAR-T cell therapy. It is for adults with certain types of large B-cell lymphoma that have not responded to or returned after initial treatment.
Boston, MassachusettsAges 18 years+ - NCT06588205Recruiting
Understanding MYC changes in aggressive B-cell lymphomas
This study looks at how changes in the MYC gene affect the outlook for people with certain fast-growing lymphomas, including diffuse large B-cell lymphoma and high-grade B-cell lymphoma. It aims to better understand the tumor environment and how these patients respond to standard chemotherapy.
AlessandriaAges 18–79 - NCT06606028Recruiting
Blood test for leftover cancer DNA after head and neck cancer treatment
This study uses a simple blood test to look for leftover cancer DNA after treatment for head and neck squamous cell carcinoma. The goal is to see if the test can find very small amounts of cancer early, which might help doctors make better decisions about follow-up care.
San Francisco, CaliforniaAges 18 years+ - NCT06716658RecruitingPhase 2
New targeted drug for certain T/NK-cell lymphomas
This trial tests an oral JAK1 inhibitor called golidocitnib for people with T/NK-cell lymphoma that came back after treatment or didn't respond. The drug works by blocking a signal that helps cancer cells grow.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06793241RecruitingEarly Phase 1
Donor CAR-T cells for B-cell leukemia
This trial tests whether CAR-T cells made from a healthy donor can help treat B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. It's for adults who cannot use their own cells for CAR-T therapy.
Hangzhou, ZhejiangAges 18 years+ - NCT06859008RecruitingPhase 1
Zanubrutinib and sonrotoclax for B-cell lymphoma in diverse groups
This trial tests two targeted drugs, zanubrutinib and sonrotoclax, together for people with certain types of B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. It focuses on enrolling patients from racial and ethnic groups that are often underrepresented in research.
Duarte, CaliforniaAges 18 years+ - NCT06863311RecruitingPhase 2
Trial of zanzalintinib with immunotherapy for advanced kidney cancer
This trial tests a new drug combination for people with advanced clear cell kidney cancer that has gotten worse after initial immunotherapy treatment. The goal is to see if adding zanzalintinib to another immunotherapy can help control the cancer.
La Jolla, CaliforniaAges 18 years+ - NCT06918912RecruitingPhase 2
Loncastuximab tesirine for lymphoma after CAR-T therapy
This trial tests a drug called loncastuximab tesirine for people with diffuse large B-cell lymphoma or high-grade B-cell lymphoma that has come back or not responded after CAR-T cell therapy. It aims to see if the drug can help when other treatments have stopped working.
Alessandria, ALESSANDRIAAges 18–99 - NCT06925464RecruitingPhase 1/Phase 2
Modified immune cells for T-cell lymphoma
This trial tests a new treatment where your own immune cells are modified to find and attack CD7-positive T-cell lymphoma cells. It is for people whose lymphoma has not responded to standard treatments.
Beijing, Beijing MunicipalityAges 14–70 - NCT06992427RecruitingPhase 3
Gabapentin to prevent opioid use for mouth pain during cancer treatment
This trial tests if taking gabapentin during chemoradiation for head and neck cancer can reduce the need for strong painkillers like opioids. It may help manage mouth pain caused by treatment.
Gilbert, ArizonaAges 18 years+ - NCT07022964RecruitingPhase 1/Phase 2
CD5 CAR T-cell therapy for relapsed or refractory T-cell lymphoma
This trial tests a new treatment called CD5 CAR T-cell therapy for people with T-cell lymphoma that has come back or not responded to standard treatments. It offers a possible option when other therapies like chemotherapy or stem cell transplant are no longer working.
BeijingAges 14–70 - NCT07058805RecruitingPhase 2
Post-radiation therapy for head and neck cancer
This trial studies a standard type of radiation therapy given after surgery for head and neck cancer. It aims to see if giving radiation only to certain areas of the neck can control the cancer with fewer side effects.
BaselAges 18 years+ - NCT07061535RecruitingPhase 2
Sintilimab, tafolecimab and chemo for advanced small cell lung cancer
This trial tests a combination of two immunotherapy drugs (sintilimab and tafolecimab) plus standard chemotherapy as a first treatment for extensive-stage small cell lung cancer. The goal is to see if adding these drugs helps people live longer and have better outcomes.
Changsha, HunanAges 18 years+ - NCT07115043RecruitingPhase 1/Phase 2
Study of AZD6750 for advanced solid tumors
This trial tests a new drug called AZD6750 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective.
Grand Rapids, MichiganAges 18 years+ - NCT07193628RecruitingPhase 1
A new immune cell therapy for recurrent glioblastoma
This trial tests a special immune cell treatment (CAR-T cells) that targets two proteins found on glioblastoma cells. It is for patients whose tumor has come back or not responded to standard treatments.
Hangzhou, ZhejiangAges 18–75 - NCT07225985RecruitingPhase 1/Phase 2
Pralatrexate, bendamustine, and radiation before donor stem cell transplant for T-cell lymphoma
This trial tests a combination of two chemotherapy drugs (pralatrexate and bendamustine) plus total-body radiation before a donor stem cell transplant for people with T-cell lymphoma that has come back or hasn't responded to treatment. The goal is to see if this approach can help destroy the lymphoma and allow the donor cells to take hold safely.
Seattle, WashingtonAges 18 years+ - NCT07252050RecruitingPhase 1/Phase 2
Ruxolitinib and half-matched transplant for severe sickle cell disease
This trial tests a new approach using the drug ruxolitinib to help a half-matched bone marrow transplant work better for people with severe sickle cell disease. It aims to reduce complications and improve outcomes.
Aurora, ColoradoAges 12–45 - NCT07283679RecruitingPhase 1/Phase 2
NK cell therapy with two immune agents for returning lymphoma
This trial tests a new combination of specially grown immune cells (NK cells) plus two drugs that help them attack cancer. It's for people with a type of B-cell lymphoma that came back after at least two prior treatments or a stem cell transplant, and who have either failed or are not eligible for CAR-T cell therapy.
Houston, TexasAges 18 years+ - NCT07285044RecruitingPhase 2
Home cancer treatment program for Florida panhandle residents
This study tests whether people with certain cancers can safely receive their regular intravenous treatments at home instead of coming to the clinic. It aims to make treatment more convenient and improve satisfaction, especially for those living in the Florida Panhandle.
Jacksonville, FloridaAges 18 years+
Hear when a new T Cells trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for t cells?
- Yes. Clin2 currently lists 5,709 recruiting t cells studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a t cells trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a t cells trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.